证券代码： 600566 证券简称： 济川药业 公告编号： 2025-049 湖北济川药业股份有限公司 1.被收购公司名称：湖北济川药业股份有限公司 2.被收购公司股票名称：济川药业 3.被收购公司股票代码：600566 4.收购股份种类：无限售条件的流通股 5.预定收购的股份数量：350,841,357 股 6.预定收购股份占被收购公司总股本比例：38.06% 7.支付方式：现金 9.要约有效期：自 2025 年 6 月 18 日至 2025 年 7 月 17 日 关于曹飞先生要约收购公司股份的第二次提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司于 2025 年 6 月 16 日披露了《湖北济川药业股份有限公司要约收购报告 书》，曹飞先生自 2025 年 6 月 18 日起要约收购公司股份 350,841,357 股。本次 要约收购的具体情况如下： 一、 本次要约收购的基本情况 8.要约价格：24.85 元/股 （鉴于公司 2024 年年度利润分配方案已实施完 毕，本次要约收购的要约收购价格 ...

国金证券股份有限公司 关于 曹飞 要约收购 湖北济川药业股份有限公司 之 独立财务顾问报告 二〇二五年七月 独立财务顾问声明和承诺 本部分所述的词语或简称与本独立财务顾问报告书"释义"部分所定义的词 语或简称具有相同的涵义。 国金证券股份有限公司接受湖北济川药业股份有限公司的委托，担任本次要 约收购的独立财务顾问。本报告所依据的有关资料由上市公司、收购人及其一致 行动人等相关机构及人员提供，并由提供方承诺对其所提供的一切书面材料、文 件或口头证言的真实性、准确性和完整性负责，并不存在虚假记载、误导性陈述 或重大遗漏。 除上市公司、收购人及其一致行动人等相关机构及人员所提供的相关信息外， 本报告所依据的其他信息均来自公开渠道，包括但不限于上市公司最近三年的定 期报告、资本市场公开数据等。 本报告仅就本次收购人要约收购上市公司事宜发表意见，包括要约收购条件 是否公平合理、收购可能对上市公司产生的影响等。对投资者根据本报告做出的 任何投资决策可能产生的后果，本独立财务顾问不承担任何责任。 截至本独立财务顾问报告出具日，本独立财务顾问与本次要约收购的所有当 事各方没有任何关联关系，本独立财务顾问就本次要约收购发表的有 ...

New Stock Offerings - Jichuan Pharmaceutical (600566) has a tender offer period from June 18, 2025, to July 17, 2025[1] - *ST Yazhen (603389) has a tender offer period from June 10, 2025, to July 9, 2025[1] - Zhongcheng Tui (300208) has 11 trading days remaining until the last trading day[1] Delisting and Trading Reminders - Tui Shi Jin Gang (600190) has 11 trading days remaining until the last trading day[1] - Hengli Tui (000622) is in the delisting arrangement period with 8 trading days remaining[1] - Tui Shi Jiu You (600462) has 7 trading days remaining until the last trading day[1] Market Volatility - Beifang Changlong (301357) reported severe abnormal fluctuations[1] - Multiple companies, including Jichuan Pharmaceutical and *ST Yazhen, are under scrutiny for trading anomalies[1]

证券代码：600566 证券简称：济川药业 公告编号：2025-048 公司于 2024 年 7 月 22 日召开了第十届董事会第十次会议、第十届监事会第 十次会议，审议通过了《关于以集中竞价交易方式回购公司股份方案的议案》，同 意公司使用自有资金通过集中竞价交易方式回购部分公司股份，用于实施员工持 股计划或股权激励。本次回购的资金总额不低于人民币 2,500 万元（含）且不超 过人民币 5,000 万元（含），回购价格不超过人民币 48 元/股（含）。回购股份实施 期限为自公司董事会审议通过回购股份方案之日起不超过 12 个月。具体内容详见 公司于 2024 年 7 月 23 日在上海证券交易所网站（http://www.sse.com.cn）披露 的《湖北济川药业股份有限公司关于以集中竞价交易方式回购公司股份方案的公 告暨回购报告书》（公告编号：2024-037）。 湖北济川药业股份有限公司关于 以集中竞价交易方式回购股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | ...

Group 1 - Hubei Province's direct financing has maintained a high level of around 800 billion yuan for three consecutive years, with nearly 80% of listed companies achieving profitability [1][2] - As of June 30, 2025, Hubei has 191 listed companies, ranking 10th nationally, with 153 domestic and 38 overseas listings [2][3] - The province has a reserve of 1,355 "gold and silver seed" enterprises to support more quality companies to go public [1][4] Group 2 - In Q1 2025, over 70% of Hubei's listed companies were profitable, with notable companies like Jiuzhoutong, CITIC Special Steel, and Wentai Technology reporting revenues exceeding 10 billion yuan [3] - The top ten companies by revenue in Hubei all exceeded 4 billion yuan, indicating strong performance in the region [3] - Hubei has implemented a comprehensive service system for companies to enter the multi-level capital market, aiming to enhance the quality of enterprises [4] Group 3 - Hubei's capital market reforms have led to 20 new listings and approvals annually from 2021 to 2023, with the province ranking 6th nationally for new listings in 2024 [2] - The province aims to achieve five major goals by 2030, including increasing the total number of listed companies and ensuring coverage across all regions [4]

New Stock Issuance - The new stock "同宇新材" (code: 301630) is listed at an issuance price of 84.00[1] - "信通电子" (code: 001388) has an issuance price of 16.42[1] Rights Issues and Announcements - "济川药业" (code: 600566) has a tender offer period from June 18, 2025, to July 17, 2025[1] - "中程退" (code: 300208) has 13 trading days remaining until the last trading day[1] - "退市锦港" (code: 600190) also has 13 trading days remaining until the last trading day[1] - "恒立退" (code: 000622) has 10 trading days remaining until the last trading day[1] Abnormal Fluctuations - "浙江东日" (code: 600113) reported severe abnormal fluctuations[1] - "汇金股份" (code: 300368) is noted for abnormal fluctuations[3]

Group 1 - A-share annual report dividend trend continues, with 198 companies distributing nearly 699 billion yuan this week [1] - China Ping An leads with a dividend of 293.34 billion yuan, followed by China General Nuclear Power and GF Securities with 47.97 billion yuan and 30.42 billion yuan respectively [1] - Over 2875 companies have completed annual report dividends, totaling nearly 977.5 billion yuan, accounting for 59.5% of the total annual dividend amount [1] Group 2 - The Shanghai Stock Exchange announced that cash dividends for Shanghai-listed companies in 2024 are expected to reach 1.8 trillion yuan, a historical high, with a dividend payout ratio of 35.6% [1][27] - Approximately 500 companies are set to issue interim dividends to meet investor cash flow needs [27] - In the past three years, 68 companies have cumulatively distributed over 10 billion yuan in cash dividends, and 872 companies have maintained a dividend payout ratio exceeding 30% for three consecutive years [27] Group 3 - The CSI Dividend ETF (515080) announced a dividend of 0.15 yuan per ten shares, with a distribution ratio of 0.99% [24][26] - This marks the 13th dividend distribution since the ETF's inception, with a cumulative dividend amount of 3.5 yuan per ten shares [26] - The ETF's annual dividend ratios over the past five years have been 4.53%, 4.14%, 4.19%, 4.78%, and 4.66% respectively [26] Group 4 - The CSI Dividend Index's total cash dividend for 2024 exceeded 920 billion yuan, setting a new historical high with a payout ratio of over 36% [20][21] - The index includes 100 constituent stocks, with China Shenhua distributing over 449 billion yuan [22][23] - The dividend distribution is part of a broader trend of increasing cash dividends among listed companies [20][21]

Core Viewpoint - Hubei Jichuan Pharmaceutical Co., Ltd. announced a cash dividend of 2.09 RMB per share as part of its 2024 annual profit distribution plan, with the record date set for June 27, 2025 [1][2] Company Announcements - The company reported a total market capitalization of 26.702 billion RMB, ranking 7th in the traditional Chinese medicine sector and 566th among all A-shares [1] - The cash dividend distribution will total approximately 1.921 billion RMB, based on 919,349,675 shares [1] - The offer price for the company's buyback will be adjusted from 48 RMB to 45.92 RMB per share, effective June 30, 2025 [2][3] - The adjusted offer price for the share buyback is set at 24.85 RMB per share due to the annual profit distribution [1][3] Dividend Taxation - For individual shareholders holding shares for over one year, the dividend income is exempt from personal income tax, resulting in a net cash dividend of 2.09 RMB per share [1] - For qualified foreign institutional investors (QFII), a 10% corporate income tax will be withheld, leading to a net cash dividend of 1.881 RMB per share [1] - Other institutional investors are responsible for their own tax payments, receiving a net cash dividend of 2.09 RMB per share [1]

Core Viewpoint - The company has announced a differentiated cash dividend distribution plan for the fiscal year 2024, with a cash dividend of 2.09 CNY per share, and adjustments to the share repurchase offer price due to this distribution [1][2]. Summary by Sections Dividend Distribution Plan - The cash dividend distribution plan was approved at the annual shareholders' meeting on May 16, 2025, with a total cash dividend payout of approximately 1.92 billion CNY based on a total share capital of 921,704,160 shares, after deducting shares in the repurchase account and restricted shares [1][2]. Adjustment of Offer Price - The offer price for the company's share repurchase will be adjusted from 26.93 CNY per share to 24.85 CNY per share, effective from June 30, 2025, due to the implementation of the 2024 annual equity distribution [1]. Calculation of Ex-Dividend Price - The ex-dividend reference price will be calculated using the formula: (previous closing price - cash dividend) / (1 + change in circulating shares ratio). The cash dividend per share, after adjustments, is approximately 2.08 CNY [2]. Relevant Dates - Key dates for the dividend distribution include: - Equity registration date: June 27, 2025 - Last trading day: June 30, 2025 - Ex-dividend date: June 30, 2025 [2]. Implementation of Distribution - The cash dividends for shareholders of unrestricted circulating shares will be distributed through the China Securities Depository and Clearing Corporation Limited, Shanghai Branch. Shareholders who have designated trading can receive their cash dividends on the distribution date [2]. Taxation on Dividends - For individual shareholders holding shares for over one year, the cash dividend of 2.09 CNY per share is exempt from personal income tax. For those holding shares for less than one year, tax will be withheld upon the sale of shares [4][6]. - For qualified foreign institutional investors (QFII), a 10% withholding tax will apply, resulting in a net cash dividend of approximately 1.881 CNY per share [6]. Contact Information - For inquiries regarding the equity distribution, shareholders can contact the company's securities affairs department at the provided phone number and email [6].

证券代码： 600566 证券简称： 济川药业 公告编号： 2025-047 湖北济川药业股份有限公司 (一) 鉴于公司实施权益分派，权益分派完成后，本次要约收购的要约收 购价格将相应调整，由 26.93 元/股拟调整为 24.85 元/股。 (二) 对于 2025 年 6 月 27 日（本次权益分派股权登记日）前及当日申报 预受要约的股东，其申报仍按调整前的要约价格 26.93 元/股执行；预受要约股 东将在要约有效期结束后，根据已预受要约且成功被收购人收购的股份数量按照 调整后的要约收购价格 24.85 元/股取得对应款项。对于 2025 年 6 月 30 日起申 报预受要约的股东，其申报按调整后的要约价格 24.85 元/股执行；预受要约股 东将在要约有效期结束后，根据已预受要约且成功被收购人收购的股份数量按照 调整后的要约收购价格 24.85 元/股取得对应款项。 (三) 对于 2025 年 6 月 27 日前、6 月 27 日以及 6 月 30 日起预受要约的股 东，本次要约收购的收购款项支付及股份交割均将在要约收购期结束后统一进行。 (四) 此次要约收购价格调整前后，本次要约收购主体及接受本次要约 ...